clinical trial · NCT07684144
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
ObesityOverweightDiabetes Mellitus, Type 2Maridebart CafraglutidePlacebo
brief summary
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
started
Jul 29, 2026
primary completion
Dec 26, 2027
completion
Mar 19, 2028
last updated
Jul 6, 2026
official title
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol